title: Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis.
authors.forename: V M
authors.initials: VM
authors.lastname: Martínez-Taboada
authors.forename: J F
authors.initials: JF
authors.lastname: Val-Bernal
authors.forename: L C
authors.initials: LC
authors.lastname: Pesquera
authors.forename: N E
authors.initials: NE
authors.lastname: Fernández-Llanio
authors.forename: J M P
authors.initials: JM
authors.lastname: Esteban
authors.forename: R
authors.initials: R
authors.lastname: Blanco
authors.forename: P
authors.initials: P
authors.lastname: Alonso-Bartolome
authors.forename: C
authors.initials: C
authors.lastname: Gonzalez-Vela
authors.forename: V
authors.initials: V
authors.lastname: Rodríguez-Valverde
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications*; D003711:Demyelinating Diseases / Q000139:chemically induced*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007279:Injections, Subcutaneous / Q000009:adverse effects; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced*
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept